Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia

This study has been completed.
Sponsor:
Information provided by:
Pediatrix Medical Group
ClinicalTrials.gov Identifier:
NCT00383318
First received: October 2, 2006
Last updated: January 24, 2008
Last verified: January 2008

October 2, 2006
January 24, 2008
September 2006
December 2007   (final data collection date for primary outcome measure)
Not Provided
Not Provided
Complete list of historical versions of study NCT00383318 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia
Demographic, Metabolic, and Genomic Description of Neonates With Severe Hyperbilirubinemia

The purpose of this study is to compare the demographic, metabolic, and genomic characteristics of patients who develop severe hyperbilirubinemia to patients who never developed a significant bilirubin level.

The purpose of this study is to compare the demographic, metabolic, and genomic characteristics of patients who develop severe hyperbilirubinemia (serum bilirubin level in the "high risk zone of greater than the 95th percentile based on the Bhutani nomogram) to patients who never developed significant hyperbilirubinemia (bilirubin level in "low risk zone of less than the 40th percentile" on Bhutani nomogram and who did not require any treatment for hyperbilirubinemia). Our primary goal is to determine if common gene mutations occur at a greater frequency in patients with severe hyperbilirubinemia than in neonates without significant hyperbilirubinemia.

The gene mutations we will test for are:

  • Glucose-6-phosphate Dehydrogenase Deficiency [G6PD] gene mutations
  • African A- mutation (G202A;A376G)
  • The common Mediterranean mutation (C563T)
  • Two common Chinese mutations (G1376T and G1388A)
  • UGT1A1 polymorphism. The UGT1A1 gene polymorphisms refer to those genetic defects found to be associated with Gilbert's Syndrome, including a promoter defect (T-3263G) that disrupts a transcription regulatory site, the TA repeats promoter polymorphism, and four mutations within the coding region (G211A, C686A, C1091T, and T1456G).
  • Gene polymorphism for the organic anion transporting protein (OATP-2)
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Not Provided
Not Provided
  • Hyperbilirubinemia
  • Jaundice
Procedure: Gene mutation sample
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
450
December 2007
December 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

Case

  • Documentation of informed consent.
  • Gestational age greater than or equal to 37 weeks.
  • Birth weight greater than or equal to 2000 grams.
  • At least one serum bilirubin level that is greater than the 95th percentile ("high risk zone") based on the Bhutani nomogram(1), for the case population.
  • Age at enrollment less than 7 days or less than or equal to 168 hours.
  • No major anomalies (chromosomal abnormalities, cyanotic congenital heart disease, gastroschisis, omphalocele, diaphragmatic hernia, or other major gastrointestinal anomalies, major neurological injury or anomaly, and multiple congenital anomalies).
  • Ability to follow subjects transferred to another facility for outcome data.

Control

  • Documentation of informed consent.
  • Gestational age greater than or equal to 37 weeks.
  • Birth weight greater than or equal to 2000 grams.
  • At least one estimate of serum bilirubin. Bilirubin level estimated to be less than the 40th percentile ("low risk zone") based on the Bhutani nomogram. While a serum bilirubin in the low risk zone is the preferred method for assessing the bilirubin level, many pediatricians use transcutaneous measure of bilirubin as a screening tool for identifying "low risk" patients. For this reason, we will allow controls to be identified using transcutaneous measurements and collect serum bilirubin levels only as clinically indicated.
  • Age at enrollment less than 7 days or less than or equal to 168 hours.
  • No major anomalies (chromosomal abnormalities, cyanotic congenital heart disease, gastroschisis, omphalocele, diaphragmatic hernia or other major gastrointestinal anomalies, major neurological injury or anomaly, and multiple congenital anomalies).
  • Ability to follow subjects transferred to another facility for outcome data.

Exclusion Criteria:

Case and Control

  • Gestational age less than 37 weeks.
  • Birth weight less than 2000 grams.
  • Older than 7 days of age or 168 hours.
  • Any major congenital anomalies.
Both
up to 6 Days
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00383318
PDX 06-001
Not Provided
Not Provided
Pediatrix Medical Group
Not Provided
Principal Investigator: Reese H Clark, MD Pediatrix Medical Group
Principal Investigator: Zhili Lin, PhD, MD Pediatrix Screening
Principal Investigator: Jon Watchko, MD University of Pittsburgh
Pediatrix Medical Group
January 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP